Pain slows lives down. It keeps athletes off the field, workers away from their jobs, and families from enjoying everyday moments. True innovation in healthcare does more than manage symptoms; it restores movement, confidence, and independence. The future of healing belongs to technologies that are gentle, precise, and designed around real people. Science becomes meaningful when it helps someone walk without discomfort, return to work sooner, or avoid unnecessary medication. That belief sits at the heart of ZetrOZ Systems.

Founded in Trumbull, Connecticut, ZetrOZ Systems stands as the global pioneer in regenerative technologies, crafting non-invasive wearable devices that revolutionize tissue healing and pain management for musculoskeletal conditions. At the heart of their mission is sustained acoustic medicine (sam^®), the only FDA-cleared multi-hour ultrasound system, born from over 30 years of medical breakthroughs and backed by more than 46 patents. Funded by the National Institutes of Health and the U.S. Department of Defense, ZetrOZ harnesses proprietary OZ Inside™ technology to deliver low-intensity, long-duration ultrasound through compact, user-friendly wearables. This approach boosts blood flow, clears inflammation, and activates the body’s natural repair processes, proven in over 30 clinical studies to speed recovery, slash pain, and cut healthcare costs by up to $30,000 per case.

With four U.S. manufacturing facilities adhering to cGMP and ISO 13585 standards, ZetrOZ has successfully treated over 300,000 patients, earning accolades like the Global Medical Innovation Award and a 90% satisfaction rate from users and providers. Driven by values of faith, patriotism, and equitable healthcare access, the company continues to expand its R&D, ensuring accessible, drug-free solutions that help 100 million people reclaim active, pain-free lives.

At CIO Bulletin, we had the privilege of interviewing Dr. George K. Lewis, Founder and CEO of ZetrOZ Systems. He shared insights into how the company helps people heal naturally, without invasive procedures or long-term medication, through clinically proven, patient-focused solutions that accelerate tissue healing and relieve chronic musculoskeletal pain in a cost-effective manner.

Interview Highlights

Could you share the inspiring story behind the inception of ZetrOZ Systems, and how your commitment to innovative science and regenerative technologies has shaped its mission to help 100 million people?

ZetrOZ Systems was founded by Dr. George Lewis, whose exposure to ultrasound and medical research began at a young age. Growing up in a laboratory environment and being surrounded by ultrasound technology shaped his understanding of how sound energy could be used to support healing. That early experience inspired a career focused on advancing therapeutic ultrasound into practical, wearable solutions. This foundation led to the development of SAM and a mission centered on helping people speed up the body’s natural healing process, stay active, and maintain independence as they age through clinically proven, at-home therapy.

What are the core products and services ZetrOZ offers, particularly in wearable medical devices, and what unique features set them apart from traditional ultrasound therapies?

ZetrOZ develops wearable medical devices powered by sustained acoustic medicine. SAM delivers long-duration therapeutic ultrasound through a lightweight, wearable system designed for daily at-home use. Unlike traditional ultrasound limited to short clinical sessions, SAM provides consistent therapy that supports healing for chronic musculoskeletal conditions and fits into an active lifestyle.

Your sustained acoustic medicine (sam^®) platform is the only FDA-cleared multi-hour ultrasound therapy available today. What makes your technology fundamentally different, and why does that distinction matter for long-term patient outcomes?

SAM is engineered to deliver a precise therapeutic dose of ultrasound over multiple hours at a clinically optimized frequency. This sustained delivery allows patients to treat themselves daily at home, which is especially important for chronic conditions associated with aging. Consistent dosing supports circulation, tissue healing, and pain reduction, leading to better long-term outcomes and an improved quality of life.

With more than three decades of innovation and a strong portfolio of federally funded research, how does ZetrOZ successfully bridge rigorous clinical science with real-world, patient-friendly wearable solutions?

Our research is built around real-world use and real patient needs. Studies focus on conditions like knee osteoarthritis and chronic tendinopathy, where sustained therapy can make a meaningful difference. By combining strong clinical evidence with wearable SAM technology, we translate science into practical solutions that patients can use comfortably every day.

Active aging is becoming a global healthcare priority. How do ZetrOZ’s wearable devices support mobility, independence, and quality of life for aging populations managing chronic musculoskeletal conditions?

SAM is designed to be easy to use, comfortable, and effective for long-term use. It has earned the Arthritis Foundation’s Ease of Use Certification and has been used for years within the VA system. By supporting healing and pain management without drugs or surgery, SAM helps aging individuals stay active, maintain mobility, and remain independent.

Your technology has been clinically validated across numerous studies and trusted by both providers and patients. What role does clinical evidence play in driving adoption among healthcare systems and insurers?

Clinical evidence is foundational to SAM adoption. Research demonstrating improved patient outcomes help healthcare systems and insurers recognize SAM as a cost-effective, wearable solution for managing chronic musculoskeletal conditions. That validation supports broader access and long-term use for aging populations.

Research and innovation remain central to your growth. Are there any upcoming products, expanded indications, or next-generation wearable solutions in the pipeline that your clients and partners should be excited about?

ZetrOZ continues to expand its SAM platform through ongoing research, an expanding patent portfolio, and next-generation wearable development. Our focus is on making SAM even more effective, easier to use, and applicable to additional chronic conditions that impact active aging.

Looking ahead to 2026 and beyond, what role do you see ZetrOZ Systems playing in shaping the future of wearable medical technology for aging populations?

ZetrOZ will continue to lead the category in wearable therapeutic ultrasound for active aging. Through ongoing research and innovation, SAM will play a growing role in helping people manage chronic conditions at home. Our focus remains on advancing wearable medical technology that supports mobility, independence, and long-term health.

The Visionary Leader behind ZetrOZ Systems’ Success

Dr. George K. Lewis, PhD, is the Founder and CEO of ZetrOZ Systems. He is a biomedical engineer with decades of experience in therapeutic ultrasound and holds more than 40 patents. His work is focused on advancing SAM as a clinically validated, patient-centered wearable technology that supports active aging.

“Our focus remains on advancing wearable medical technology that supports mobility, independence, and long-term health.”